Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| PROCEPT BioRobotics | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Comparative analysis of efficacy and safety of Aquablation (AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA) and transurethral laser enucleation as surgical therapy for benign prostatic hyperplasia with large prostates (80-180ml).
Prospective randomized and non-randomized cohort, two-arm multicenter trial two arm multicenter trial to evaluate the efficacy and safety of Aquablation (AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA) compared to transurethral laser enucleation - the current reference standard of minimal invasive therapy for benign prostatic hyperplasia in large prostates (80-180ml).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aquablation therapy | Active Comparator | Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR). |
|
| Transurethral laser enucleation | Active Comparator | Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aquablation therapy | Procedure | Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Efficacy Endpoint | Primary efficacy endpoint is defined as IPSS (International Prostate Symptom Score) change | 3 months after index procedure |
| Primary Safety Endpoint | Primary safety endpoint is defined as the occurrence of an Adverse Event rated by the investigator as related or unrelated to the study procedure, classified as Clavien Dindo grade 2 or higher or any grade 1 event resulting in persistent disability, such as ejaculatory or erectile dysfunction or incontinence, as evidenced through 3 months after treatment. | Through 3 months after index procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Change in IPSS | Change in IPSS (International Prostate Symptom Score) | 1,6,12,24,36,48 and 60 months after index procedure |
| Change in IIEF 5/SHIM | Change in IIEF5/SHIM (International Index of Erectile Function) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Manuel Ritter, Univ.-Prof. Dr. med. | Department of Urology, University of Bonn | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Urology, University Hospital Freiburg | Freiburg im Breisgau | Baden-Wurttemberg | 79106 | Germany | ||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
randomized and non-randomized trial
Not provided
Not provided
Not provided
Not provided
| Transurethral laser enucleation | Procedure | Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP). |
|
| 3,6,12,24,36,48 and 60 months after index procedure |
| Change in MSHQ-EjD-SF | Change in MSHQ-EjD-SF (Male Sexual Health Questionnaire for Ejaculatory Dysfunction Short Form) | 3,6,12,24,36,48 and 60 months after index procedure |
| Change in Dysuria Questionnaire | Change in Dysuria Questionnaire | 1,3,6,12,24,36,48 and 60 months after index procedure |
| Change in ICIQ-UI-SF | Change in ICIQ-UI-SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form) | 1,3,6,12, 24,36,48 and 60 months after index procedure |
| Post void residual urine | Reduction of Post void residual urine | day 2-5, 3 months, 6 months, 12 months and 36 months after index procedure |
| Qmax, Uroflowmetry | Changes of maximum flow rate (Qmax) measured by Uroflowmetry | day 2-5, 3 months, 6 months, 12 months and 36 months after index procedure |
| Prostate volume reduction | Prostate volume reduction | comparison of Visit 5 (3 months) and visit 1 (baseline) |
| Number of re-interventions | Number of re-interventions defined as need for additional tissue resection following the index procedure due to BPH. | Through 60 months after index procedure |
| Department of Urology, Augusta-Kranken-Anstalt, Bochum Mitte |
| Bochum |
| North Rhine-Westphalia |
| 44791 |
| Germany |
| Department of Urology, University Hospital Bonn | Bonn | North Rhine-Westphalia | 53127 | Germany |
| Frimley Health NHS Foundation Trust | London | United Kingdom |
| Guy's and St. Thomas' Hospital | London | United Kingdom |